Peer-reviewed veterinary case report
15-week CHOP chemo for treating dog multicentric lymphoma
By Burton, J. H. et al.·Published in Veterinary and Comparative Oncology·2012·Animal Cancer Center, Department of Clinical Sciences Colorado State University Fort Collins CO USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of a 15‐weekCHOPprotocol for the treatment of canine multicentric lymphoma
- Species:
- dog
Plain-English summary
A group of 31 dogs with multicentric lymphoma (a type of cancer affecting the lymph nodes) underwent a 15-week chemotherapy treatment plan called CHOP. Remarkably, all the dogs responded positively to the treatment, with an average time before the cancer progressed being about 140 days. Interestingly, dogs that had to pause treatment due to side effects ended up having better overall survival rates. This suggests that adjusting the dose based on each dog's tolerance could be beneficial for their treatment outcomes.
People also search for: dog lymphoma treatment options · CHOP chemotherapy for dogs · canine cancer survival rates
Abstract
AbstractDose intenseCHOPprotocols have been shown to improve outcome for people with non‐Hodgkin's lymphoma, but evaluation of dose intenseCHOPprotocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15‐week dose intenseCHOPprotocol would have shorter treatment duration with similar efficacy to other doxorubicin‐based multidrug protocols. Thirty‐one client owned dogs with multicentric lymphoma were treated with a 15‐weekCHOPchemotherapy protocol with an overall response rate of 100% and a median progression‐free interval (PFI) of 140 days [95% confidence interval (CI) 91–335 days]. Dogs that had two or more treatment delays had significantly prolongedPFIand overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1476-5829.2012.00324.x